Search

Your search keyword '"Kersten, Marie José"' showing total 602 results
Start Over Author "Kersten, Marie José" Search Limiters Full Text
602 results on '"Kersten, Marie José"'

3. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

Author

de Jonge, A. Vera, van Werkhoven, Erik, Dinmohamed, Avinash G., Nijland, Marcel, Zwinderman, Aeilko H., Bossuyt, Patrick M., Veldhuis, Martine S., Rutten, Emma G. G. M., Mous, Rogier, Vermaat, Joost S. P., Sandberg, Yorick, de Jongh, Eva, Bilgin, Yavuz M., Boersma, Rinske, Koene, Harry, Kersten, Marie José, de Jong, Daphne, and Chamuleau, Martine E. D.

Published
2023
Full Text
View/download PDF

4. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

Author

Brink, Mirian, Huisman, Francien, Meeuwes, Frederik O., van der Poel, Marjolein W. M., Kersten, Marie José, Wondergem, Mariëlle, Böhmer, Lara, Woei-A-Jin, F. J. Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Diepstra, Arjan, Snijders, Tjeerd J. F., Huls, Gerwin, Vermaat, Joost S. P., Plattel, Wouter J., and Nijland, Marcel

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials

Author

Westin, Jason R, Kersten, Marie José, Salles, Gilles, Abramson, Jeremy S, Schuster, Stephen J, Locke, Frederick L, and Andreadis, Charalambos

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Hematology, Orphan Drug, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Biotechnology, Lymphoma, Clinical Research, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Antigens, CD19, Biological Products, Clinical Trials as Topic, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, Receptors, Antigen, T-Cell, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Chimeric antigen receptor (CAR)-T cell therapies have improved the outcome for many patients with relapsed or refractory aggressive B-cell lymphomas. In 2017, axicabtagene ciloleucel and soon after tisagenlecleucel became the first approved CAR-T cell products for patients with high-grade B-cell lymphomas or diffuse large B-cell lymphoma (DLBCL) who are relapsed or refractory to ≥ 2 prior lines of therapy; lisocabtagene maraleucel was approved in 2021. Safety and efficacy outcomes from the pivotal trials of each CAR-T cell therapy have been reported. Despite addressing a common unmet need in the large B-cell lymphoma population and utilizing similar CAR technologies, there are differences between CAR-T cell products in manufacturing, pivotal clinical trial designs, and data reporting. Early reports of commercial use of axicabtagene ciloleucel and tisagenlecleucel provide the first opportunities to validate the impact of patient characteristics on the efficacy and safety of these CAR-T cell therapies in the real world. Going forward, caring for patients after CAR-T cell therapy will require strategies to monitor patients for sustained responses and potential long-term side effects. In this review, product attributes, protocol designs, and clinical outcomes of the key clinical trials are presented. We discuss recent data on patient characteristics, efficacy, and safety of patients treated with axicabtagene ciloleucel or tisagenlecleucel in the real world. Finally, we discuss postinfusion management and preview upcoming clinical trials of CAR-T cell therapies.

Published
2021

8. Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial.

Author

Starreveld, Daniëlle EJ, Daniels, Laurien A, Kieffer, Jacobien M, Valdimarsdottir, Heiddis B, de Geus, Jessie, Lanfermeijer, Mirthe, van Someren, Eus JW, Habers, G Esther A, Bosch, Jos A, Janus, Cécile PM, van Spronsen, Dick Johan, de Weijer, Roel J, Marijt, Erik WA, de Jongh, Eva, Zijlstra, Josée M, Böhmer, Lara H, Houmes, Margreet, Kersten, Marie José, Korse, Catharina M, van Rossum, Huub H, Redd, William H, Lutgendorf, Susan K, Ancoli-Israel, Sonia, van Leeuwen, Flora E, and Bleiker, Eveline MA

Subjects
cancer-related fatigue, circadian rhythms, light therapy, randomized controlled trial, sleep, Clinical Research, Depression, Rehabilitation, Rare Diseases, Lymphoma, Cancer, Clinical Trials and Supportive Activities, Behavioral and Social Science, Sleep Research, Hematology, Mental Health, Oncology and Carcinogenesis
Abstract

PurposeTo evaluate the short- and long-term effects of light therapy on fatigue (primary outcome) and sleep quality, depression, anxiety, quality of life, and circadian rhythms (secondary outcomes) in survivors of (non-)Hodgkin lymphoma presenting with chronic cancer-related fatigue.MethodsWe randomly assigned 166 survivors (mean survival 13 years) to a bright white light intervention (BWL) or dim white light comparison (DWL) group. Measurements were completed at baseline (T0), post-intervention (T1), at three (T2), and nine (T3) months follow-up. A mixed-effect modeling approach was used to compare linear and non-linear effects of time between groups.ResultsThere were no significant differences between BWL and DWL in the reduction in fatigue over time. Both BWL and DWL significantly (p < 0.001) improved fatigue levels during the intervention followed by a slight reduction in this effect during follow-up (EST0-T1 = -0.71; EST1-T3 = 0.15). Similar results were found for depression, sleep quality, and some aspects of quality of life. Light therapy had no effect on circadian rhythms.ConclusionsBWL was not superior in reducing fatigue compared to DWL in HL and DLBCL survivors. Remarkably, the total sample showed clinically relevant and persistent improvements on fatigue not commonly seen in longitudinal observational studies in these survivors.

Published
2021

9. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Author

Oluwole, Olalekan O, Bouabdallah, Krimo, Muñoz, Javier, De Guibert, Sophie, Vose, Julie M, Bartlett, Nancy L, Lin, Yi, Deol, Abhinav, McSweeney, Peter A, Goy, Andre H, Kersten, Marie José, Jacobson, Caron A, Farooq, Umar, Minnema, Monique C, Thieblemont, Catherine, Timmerman, John M, Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Kim, Jenny J, Bashir, Zahid, McLeroy, Jeff, Zheng, Yan, Rossi, John M, Johnson, Lisa, Goyal, Lovely, and Meerten, Tom

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Rare Diseases, Cancer, Hematology, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Biological Products, Cytokine Release Syndrome, Dexamethasone, Female, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, large B-cell lymphoma, axi-cel, chimaeric antigen receptor-T cell, prophylaxis, corticosteroids, cytokine release syndrome, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several exploratory safety management cohorts were added to ZUMA-1. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end-points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days -5 through -3), 2 × 106  CAR-T cells/kg (day 0) and once-daily oral dexamethasone [10 mg, day 0 (before axi-cel) through day 2]. Forty patients received axi-cel. CRS occurred in 80% of patients (all grade ≤2). Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients respectively. Sixty-eight per cent of patients did not experience CRS or NEs within 72 h of axi-cel. With a median follow-up of 8·9 months, objective and complete response rates were 95% and 80% respectively. Overall, prophylactic corticosteroids and earlier corticosteroid and/or tocilizumab intervention resulted in no grade 3 or higher CRS, a low rate of grade 3 or higher NEs and high response rates in this study population.

Published
2021

15. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Author

Elsawy, Mahmoud, Chavez, Julio C., Avivi, Irit, Larouche, Jean-François, Wannesson, Luciano, Cwynarski, Kate, Osman, Keren, Davison, Kelly, Rudzki, Jakob D., Dahiya, Saurabh, Dorritie, Kathleen, Jaglowski, Samantha, Radford, John, Morschhauser, Franck, Cunningham, David, Martin Garcia-Sancho, Alejandro, Tzachanis, Dimitrios, Ulrickson, Matthew L., Karmali, Reem, Kekre, Natasha, Thieblemont, Catherine, Enblad, Gunilla, Dreger, Peter, Malladi, Ram, Joshi, Namita, Wang, Wei-Jhih, Solem, Caitlyn T., Snider, Julia Thornton, Cheng, Paul, To, Christina, and Kersten, Marie José

Published
2022
Full Text
View/download PDF

16. Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Author

Ghobadi, Armin, primary, Munoz, Javier, additional, Westin, Jason R, additional, Locke, Frederick L, additional, Miklos, David B, additional, Rapoport, Aaron P., additional, Perales, Miguel-Angel, additional, Reagan, Patrick M, additional, McGuirk, Joseph P, additional, Jacobson, Caron A., additional, Kersten, Marie José, additional, Avivi, Irit, additional, Peng, Andrew, additional, Schupp, Marco, additional, To, Christina, additional, and Oluwole, Olalekan O, additional

Published
2024
Full Text
View/download PDF

17. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Author

Fowler, Nathan Hale, Dickinson, Michael, Dreyling, Martin, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, José Antonio, Chen, Andy I., Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andrés José María, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Zia, Aiesha, Awasthi, Rakesh, Masood, Aisha, Anak, Oezlem, Schuster, Stephen J., and Thieblemont, Catherine

Published
2022
Full Text
View/download PDF

18. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

Author

Los-de Vries, G. Tjitske, Stevens, Wendy B.C., van Dijk, Erik, Langois-Jacques, Carole, Clear, Andrew J., Stathi, Phylicia, Roemer, Margaretha G.M., Mendeville, Matias, Hijmering, Nathalie J., Sander, Birgitta, Rosenwald, Andreas, Calaminici, Maria, Hoster, Eva, Hiddemann, Wolfgang, Gaulard, Philippe, Salles, Gilles, Horn, Heike, Klapper, Wolfram, Xerri, Luc, Burton, Catherine, Tooze, Reuben M., Smith, Alexandra G., Buske, Christian, Scott, David W., Natkunam, Yasodha, Advani, Ranjana, Sehn, Laurie H., Raemaekers, John, Gribben, John, Kimby, Eva, Kersten, Marie José, Maucort-Boulch, Delphine, Ylstra, Bauke, and de Jong, Daphne

Published
2022
Full Text
View/download PDF

19. Impact of etoposide and ASCT on survival among patients aged

Author

Brink, Mirian, Meeuwes, Frederik O., van der Poel, Marjolein W.M., Kersten, Marie José, Wondergem, Mariëlle, Mutsaers, Pim G.N.J., Böhmer, Lara H., Woei-A-Jin, F. J. Sherida H., Visser, Otto, Oostvogels, Rimke, Jansen, Patty M., Plattel, Wouter, Huls, Gerwin A., Vermaat, Joost S.P., and Nijland, Marcel

Published
2022
Full Text
View/download PDF

21. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Author

de Groen, Ruben A.L., van Eijk, Ronald, Böhringer, Stefan, van Wezel, Tom, Raghoo, Richard, Ruano, Dina, Jansen, Patty M., Briaire-de Bruijn, Inge, de Groot, Fleur A., Kleiverda, Karin, te Boome, Liane, Terpstra, Valeska, Levenga, Henriette, Nicolae, Alina, Posthuma, Eduardus F.M., Focke-Snieders, Isabelle, Hardi, Lizan, den Hartog, Wietske C.E., Bohmer, Lara H., Hogendoorn, Pancras C.W., van den Berg, Anke, Diepstra, Arjan, Nijland, Marcel, Lugtenburg, Pieternella J., Kersten, Marie José, Pals, Steven T., Veelken, Hendrik, Bovée, Judith V.M.G., Cleven, Arjen H.G., and Vermaat, Joost S.P.

Published
2021
Full Text
View/download PDF

22. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

Author

Brink, Mirian, Kahle, Xaver U., Vermaat, Joost S.P., Zijlstra, Josee M., Chamuleau, Martine, Kersten, Marie José, Durmaz, Müjde, Plattel, Wouter J., Lugtenburg, Pieternella J., Stevens, Wendy, Mous, Rogier, de Vries, Elisabeth G.E., van der Poel, Marjolein W.M., Panday, Prashant V. Nannan, Huls, Gerwin, van Meerten, Tom, and Nijland, Marcel

Published
2021
Full Text
View/download PDF

23. Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities

Author

de Boer, Janneke W., primary, Keijzer, Kylie, additional, Pennings, Elise R. A., additional, van Doesum, Jaap A., additional, Spanjaart, Anne M., additional, Jak, Margot, additional, Mutsaers, Pim G. N. J., additional, van Dorp, Suzanne, additional, Vermaat, Joost S. P., additional, van der Poel, Marjolein W. M., additional, van Dijk, Lisanne V., additional, Kersten, Marie José, additional, Niezink, Anne G. H., additional, and van Meerten, Tom, additional

Published
2023
Full Text
View/download PDF

24. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

Author

de Boer, Janneke W., primary, Pennings, Elise R. A., additional, Kleinjan, Ankie, additional, van Doesum, Jaap A., additional, Spanjaart, Anne M., additional, Mutsaers, Pim G. N. J., additional, Jak, Margot, additional, van der Poel, Marjolein W. M., additional, Kuipers, Maria T., additional, Adam, Judit A., additional, Diepstra, Arjan, additional, Koens, Lianne, additional, van Dorp, Suzanne, additional, Vermaat, Joost S. P., additional, Niezink, Anne G. H., additional, Kersten, Marie José, additional, and van Meerten, Tom, additional

Published
2023
Full Text
View/download PDF

28. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Author

Awasthi, Rakesh, Pacaud, Lida, Waldron, Edward, Tam, Constantine S., Jäger, Ulrich, Borchmann, Peter, Jaglowski, Samantha, Foley, Stephen Ronan, van Besien, Koen, Wagner-Johnston, Nina D., Kersten, Marie José, Schuster, Stephen J., Salles, Gilles, Maziarz, Richard T., Anak, Özlem, del Corral, Christopher, Chu, Jufen, Gershgorin, Irina, Pruteanu-Malinici, Iulian, Chakraborty, Abhijit, Mueller, Karen Thudium, and Waller, Edmund K.

Published
2020
Full Text
View/download PDF

29. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands

Author

Meeuwes, Frederik O., primary, Brink, Mirian, additional, Plattel, Wouter, additional, Van der Poel, Marjolein W.M., additional, Kersten, Marie José, additional, Wondergem, Mariëlle, additional, Böhmer, Lara, additional, Woei-A-Jin, F.J. Sherida H., additional, Visser, Otto, additional, Oostvogels, Rimke, additional, Jansen, Patty M., additional, Neelis, Karen J., additional, Crijns, Anne P.G., additional, Daniëls, Laurien A., additional, Snijders, Tjeerd J.F., additional, Vermaat, Joost S.P., additional, Huls, Gerwin A., additional, and Nijland, Marcel, additional

Published
2023
Full Text
View/download PDF

30. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Author

Spanjaart, Anne M., primary, Pennings, Elise R. A., additional, Mutsaers, Pim G. N. J., additional, van Dorp, Suzanne, additional, Jak, Margot, additional, van Doesum, Jaap A., additional, de Boer, Janneke W., additional, Niezink, Anne G. H., additional, Kos, Milan, additional, Vermaat, Joost S. P., additional, Sijs-Szabo, Aniko, additional, van der Poel, Marjolein W. M., additional, Nijhof, Inger S., additional, Kuipers, Maria T., additional, Chamuleau, Martine E. D., additional, Lugtenburg, Pieternella J., additional, Doorduijn, Jeanette K., additional, Serroukh, Yasmina I. M., additional, Minnema, Monique C., additional, van Meerten, Tom, additional, and Kersten, Marie José, additional

Published
2023
Full Text
View/download PDF

31. No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study

Author

Geerdes, Emma E., primary, Durmaz, Müjde, additional, Lugtenburg, Pieternella J., additional, Chamuleau, Martine E. D., additional, Visser, Otto, additional, Issa, Djamila E., additional, Brouwer, Rolf E., additional, Posthuma, Eduardus F. M., additional, Zijlstra, Josée M., additional, Kersten, Marie José, additional, and Dinmohamed, Avinash G., additional

Published
2023
Full Text
View/download PDF

35. NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

Author

Verkleij, Christie P.M., primary, Frerichs, Kristine A., additional, Broekmans, Marloes E.C., additional, Duetz, Carolien, additional, O’Neill, Chloe A., additional, Bruins, Wassilis S.C., additional, Homan-Weert, Paola M., additional, Minnema, Monique C., additional, Levin, Mark-David, additional, Broijl, Annemiek, additional, Bos, Gerard M.J., additional, Kersten, Marie José, additional, Klein, Saskia K., additional, Shikhagaie, Medya M., additional, Casneuf, Tineke, additional, Abraham, Yann, additional, Smets, Tina, additional, Vanhoof, Greet, additional, Cortes-Selva, Diana, additional, van Steenbergen, Laure, additional, Ramos, Elena, additional, Verona, Raluca I., additional, Krevvata, Maria, additional, Sonneveld, Pieter, additional, Zweegman, Sonja, additional, Mutis, Tuna, additional, and van de Donk, Niels W.C.J., additional

Published
2023
Full Text
View/download PDF

39. Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Author

Stevens, Wendy B. C., primary, Los-de Vries, G. Tjitske, additional, Langois-Jacques, Carole, additional, Clear, Andrew J., additional, Stathi, Phylicia, additional, Sander, Birgitta, additional, Rosenwald, Andreas, additional, Calaminici, Maria, additional, Hoster, Eva, additional, Hiddemann, Wolfgang, additional, Gaulard, Philippe, additional, Salles, Gilles, additional, Klapper, Wolfram, additional, Xerri, Luc, additional, Burton, Catherine, additional, Tooze, Reuben M., additional, Smith, Alexandra G., additional, Buske, Christian, additional, Scott, David W., additional, Natkunam, Yasodha, additional, Advani, Ranjana, additional, Sehn, Laurie H., additional, Raemaekers, John, additional, Gribben, John, additional, Lockmer, Sandra, additional, Kimby, Eva, additional, Kersten, Marie José, additional, Maucort-Boulch, Delphine, additional, Ylstra, Bauke, additional, van Dijk, Erik, additional, and de Jong, Daphne, additional

Published
2023
Full Text
View/download PDF

40. Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study

Author

Vinke, Petra C., primary, Combalia, Marc, additional, de Bock, Geertruida H, additional, Leyrat, Clémence, additional, Spanjaart, Anne Mea, additional, Dalle, Stephane, additional, Gomes da Silva, Maria, additional, Fouda Essongue, Aurore, additional, Rabier, Aurélie, additional, Pannard, Myriam, additional, Jalali, Mohammad S, additional, Elgammal, Amal, additional, Papazoglou, Mike, additional, Hacid, Mohand-Said, additional, Rioufol, Catherine, additional, Kersten, Marie-José, additional, van Oijen, Martijn GH, additional, Suazo-Zepeda, Erick, additional, Malhotra, Ananya, additional, Coquery, Emmanuel, additional, Anota, Amélie, additional, Preau, Marie, additional, Fauvernier, Mathieu, additional, Coz, Elsa, additional, Puig, Susana, additional, and Maucort-Boulch, Delphine, additional

Published
2023
Full Text
View/download PDF

41. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., additional, Dickinson, Michael, additional, Ghobadi, Armin, additional, Elsawy, Mahmoud, additional, van Meerten, Tom, additional, Miklos, David B., additional, Ulrickson, Matthew L., additional, Perales, Miguel-Angel, additional, Farooq, Umar, additional, Wannesson, Luciano, additional, Leslie, Lori, additional, Kersten, Marie José, additional, Jacobson, Caron A., additional, Pagel, John M., additional, Wulf, Gerald, additional, Johnston, Patrick, additional, Rapoport, Aaron P., additional, Du, Linqiu, additional, Vardhanabhuti, Saran, additional, Filosto, Simone, additional, Shah, Jina, additional, Snider, Julia T., additional, Cheng, Paul, additional, To, Christina, additional, Oluwole, Olalekan O., additional, and Sureda, Anna, additional

Published
2023
Full Text
View/download PDF

42. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study

Author

Ghobadi, Armin, primary, Muñoz, Javier, additional, Westin, Jason R., additional, Locke, Frederick L., additional, Miklos, David B., additional, Rapoport, Aaron P., additional, Perales, Miguel-Angel, additional, Reagan, Patrick M., additional, McGuirk, Joseph P., additional, Jacobson, Caron A., additional, Kersten, Marie José, additional, Avivi, Irit, additional, Peng, Andrew, additional, Schupp, Marco, additional, To, Christina, additional, and Oluwole, Olalekan O., additional

Published
2023
Full Text
View/download PDF

43. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Zuma-7

Author

Locke, Frederick L., primary, Oluwole, Olalekan O., additional, Kuruvilla, John, additional, Thieblemont, Catherine, additional, Morschhauser, Franck, additional, Salles, Gilles, additional, Rowe, Steven P., additional, Vardhanabhuti, Saran, additional, Filosto, Simone, additional, To, Christina, additional, Cheng, Paul, additional, Schupp, Marco, additional, Korn, Ronald, additional, and Kersten, Marie José, additional

Published
2023
Full Text
View/download PDF

44. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6

Author

Oluwole, Olalekan O., primary, Forcade, Edouard, additional, Muñoz, Javier, additional, de Guibert, Sophie, additional, Vose, Julie M., additional, Bartlett, Nancy L., additional, Lin, Yi, additional, Deol, Abhinav, additional, McSweeney, Peter A., additional, Goy, Andre H., additional, Kersten, Marie José, additional, Jacobson, Caron A., additional, Farooq, Umar, additional, Minnema, Monique C., additional, Thieblemont, Catherine, additional, Timmerman, John M., additional, Stiff, Patrick, additional, Avivi, Irit, additional, Tzachanis, Dimitrios, additional, Zheng, Yan, additional, Vardhanabhuti, Saran, additional, Nater, Jenny, additional, Shen, Rhine R., additional, Miao, Harry, additional, Kim, Jenny J., additional, and van Meerten, Tom, additional

Published
2023
Full Text
View/download PDF

45. Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data

Author

VAN VULPEN, JONNA K., SWEEGERS, MAIKE G., PEETERS, PETRA H. M., COURNEYA, KERRY S., NEWTON, ROBERT U., AARONSON, NEIL K., JACOBSEN, PAUL B., GALVÃO, DANIEL A., CHINAPAW, MAI J., STEINDORF, KAREN, IRWIN, MELINDA L., STUIVER, MARTIJN M., HAYES, SANDI, GRIFFITH, KATHLEEN A., MESTERS, ILSE, KNOOP, HANS, GOEDENDORP, MARTINE M., MUTRIE, NANETTE, DALEY, AMANDA J., MCCONNACHIE, ALEX, BOHUS, MARTIN, THORSEN, LENE, SCHULZ, KARL-HEINZ, SHORT, CAMILLE E., JAMES, ERICA L., PLOTNIKOFF, RONALD C., SCHMIDT, MARTINA E., ULRICH, CORNELIA M., VAN BEURDEN, MARC, OLDENBURG, HESTER S., SONKE, GABE S., VAN HARTEN, WIM H., SCHMITZ, KATHRYN H., WINTERS-STONE, KERRI M., VELTHUIS, MIRANDA J., TAAFFE, DENNIS R., VAN MECHELEN, WILLEM, KERSTEN, MARIE JOSÉ, NOLLET, FRANS, WENZEL, JENNIFER, WISKEMANN, JOACHIM, VERDONCK-DE LEEUW, IRMA M., BRUG, JOHANNES, MAY, ANNE M., and BUFFART, LAURIEN M.

Published
2020
Full Text
View/download PDF

46. SMG1 , a nonsense‐mediated mRNA decay ( NMD ) regulator, as a candidate therapeutic target in multiple myeloma

Author

Leeksma, Alexander C., primary, Derks, Ingrid A. M., additional, Garrick, Brett, additional, Jongejan, Aldo, additional, Colombo, Martino, additional, Bloedjes, Timon, additional, Trowe, Torsten, additional, Leisten, Jim C., additional, Howarth, Michelle, additional, Malek, Mehnaz, additional, Mortensen, Deborah S., additional, Blease, Kate, additional, Groza, Mathew C., additional, Narla, Rama Krishna, additional, Loos, Remco, additional, Kersten, Marie‐José, additional, Moerland, Perry D., additional, Guikema, Jeroen E. J., additional, Kater, Arnon P., additional, Eldering, Eric, additional, and Filvaroff, Ellen H., additional

Published
2022
Full Text
View/download PDF

48. Therapies and Outcomes for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Contemporary, Nationwide, Population-Based Study in the Netherlands

Author

Pennings, Elise R.A., primary, Durmaz, Müjde, additional, Visser, Otto, additional, Posthuma, Eduardus F.M., additional, Issa, Djamila E., additional, Chamuleau, Martine E.D., additional, Lugtenburg, Pieternella, additional, Kersten, Marie José, additional, and Dinmohamed, Avinash G., additional

Published
2022
Full Text
View/download PDF

49. Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Author

Borchmann, Peter, primary, Vandenberghe, Peter, additional, Urbano-Ispizua, Alvaro, additional, Haioun, Corinne, additional, Lemonnier, Francois, additional, Griskevicius, Laimonas, additional, Maury, Sébastien, additional, Holtkamp, Silke, additional, Friedrichs, Birte, additional, Zadoyan, Gregor, additional, Hanssens, Linda, additional, Overstijns, Toon, additional, Assenmacher, Mario, additional, Bethke, Ulf, additional, Bürger, Iris, additional, Reer, Olaf, additional, Jaeger, Ulrich, additional, and Kersten, Marie José, additional

Published
2022
Full Text
View/download PDF

50. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results